
Rising rates of cancer in young people: nature or nurture?
High-quality studies employing molecular pathological epidemiology frameworks could help pinpoint aetiologic mechanisms and help tackle a potential future epidemic among the youngest

Multi-cancer early detection – promise or reality?
While there has been significant progress in the development of these blood tests, hurdles remain including test sensitivity and false positives

Does artificial intelligence have a place in precision oncology?
Applications in artificial intelligence have the potential to transform precision oncology, but data quality and clinical validation of tools are still challenging

Breastfeeding after breast cancer is feasible and safe
New data show that it does not increase the risk of breast cancer recurrence or development of secondary breast cancer in women, nor does it carry any health risks for the child

Leveraging team science to exploit the tumour’s ‘Achilles heel’ with PARP inhibition: a journey of discovery and perseverance
Extensive research identified the deficiency of a highly accurate DNA repair process known as homologous recombination as an ‘Achilles heel’ in cancer, and led to the development of PARP inhibitors as single-agent therapies

Choose the right treatment, at the right dose – a way to create a financially-sustainable cancer care?
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology

Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population

Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease

Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management

Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care